Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 3NET 1Genitourinary 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 35Carcinoid Tumor 8Adenoma, Islet Cell 6Neoplasms 5Neoplasm Metastasis 3Carcinoma, Neuroendocrine 3Neuroectodermal Tumors, Primitive 2Liver Neoplasms 2Gastro-enteropancreatic neuroendocrine tumor 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Carcinoma 2Tuberous Sclerosis 1Thymus Neoplasms 1Pheochromocytoma 1Paraganglioma 1Pancreatic Neuroendocrine Tumors 1Pancreatic Neoplasms 1Neoplastic Cells, Circulating 1Multiple Endocrine Neoplasia Type 1 1Metatropic dwarfism 1Metastatic Digestive System Neuroendocrine Tumor G1 1Lymphoma, Follicular 1Lung Neoplasms 1Kidney Neoplasms 1Glioblastoma 1Gastroenteropancreatic Neuroendocrine Tumors 1Disease Progression 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Large Cell 1

Interventions

exemestane 1Injections 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Tuberous Sclerosis × Everolimus × NET × Clear all
NCT07369505 2026-01-27

Sapu003 in Advanced mTOR-sensitive Solid Tumors

SAPU NANO (US) LLC

Phase 1 Recruiting
27 enrolled
EndocrineGastrointestinalGenitourinaryNET

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Tuberous Sclerosis, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡